Breast cancer patients prefer knowing costs prior to starting treatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Even when they had good health insurance coverage, women with breast cancer reported having financial worries related to their care, and the vast majority said they preferred to know about treatment costs at the time of diagnosis.

The findings from a study by Duke Cancer Institute researchers highlight the importance of considering medical costs as women face breast cancer treatment decisions.

The vast majority of women—eight out of 10—said they preferred knowing the costs of treatment prior to embarking on cancer care. And 40 percent preferred that doctors consider costs when making treatment recommendations.

In the study, the Duke team surveyed more than 750 women after breast cancer from the Army of Women and Sisters Network, national organizations of women after breast cancer. All were women with a median age of about 50. Most had either private health insurance or Medicare, and had annual household income of more than $74,000.

Even within this group—financially better off than many cancer patients—nearly 16 percent reported significant to catastrophic financial burden.

Median reported out-of-pocket costs were $3,500, although 5 percent of women faced out-of-pocket costs over $30,000.

Table of Contents

YOU MAY BE INTERESTED IN

“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. https://open.spotify.com/episode/2PFYGwliBDYEbxBXFd9MtB?si=95DNBAy0QGSKBX31_uETEA This episode is available on Spotify, Apple Podcasts, and Youtube. Letai recapped his first year as NCI director in conversation with Paul Goldberg,...

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login